Actively Recruiting
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-11
168
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is: What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP. Participants wil: * take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests
CONDITIONS
Official Title
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospitalized with Community-Acquired Pneumonia confirmed by chest imaging and clinical symptoms such as fever, cough, and sputum
- Age greater than 18 years
- Provided informed consent
You will not qualify if you...
- History of cancer within the last 3 years except for successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix
- Active inflammatory conditions like rheumatoid arthritis, chronic inflammatory bowel disease, or systemic lupus erythematosus
- Use of systemic anti-inflammatory therapy such as prednisone or methotrexate
- Pregnancy or breastfeeding
- Women of childbearing potential who refuse to use two forms of contraception during the study
- Men capable of fathering a child who refuse to use contraception
- Allergies to icosapent ethyl
- Allergies to fish or shellfish
- Glomerular filtration rate less than 50 ml/min/1.72m2
- Unable to give informed consent
- Allergy to dye preventing CTA imaging (excluded from CTA portion but still eligible for PET/CT)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
Research Team
K
Kevin Boczar, MD
CONTACT
A
Ashley Cowan, BScN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here